R.PR
REGISTERED-PRINCIPAL REGISTER
12/14/2021
Back to search
Official data from USPTO
STAIDSON
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
8
Latest update
12/14/2021
Trademark type
Combined
Nice classes
5
Filing date
02/03/2021
Registration date
12/14/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/14/2021
Last transaction
12/14/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
BEIJING, CN
Examiner
LEE,YATSYE ISADORA
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of stylized word "STAIDSON".
Holders and representatives
Holders
Staidson (Beijing) Biopharmaceuticals Co., Ltd.
Representatives
PAULO A. DE ALMEIDA PATEL & ALMEIDA, P. C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for human purposesfor the treatment of injury of nerve; Medicines for human purposesfor the treatment of functional constipation and/or for the intestinal cleaning preparation; Medicines for human purposesfor the treatment of diabetes; Medicines for human purposesfor the treatment of treatment of reproductive system related diseases; Acetylsalicylic acid tablets; Medicines for human purposesfor the treatment of diabetic foot; Medicines for human purposesfor treatment of hyperuricemia; Medicines for human purposesfor hemostasis; Medicines for human purposesfor the treatment of hepatitis BAidsretinal pigment degeneration and glioma; Medicines for human purposesfor the treatment of frequent micturitionurgency of urination and urge urinary incontinence; Supplementary medicines for human purposesfor the treatment of pain of muscle cramp caused by inflammation and injury; Medicines for human purposesfor the treatment of gastric ulcerduodenal ulcer and chronic gastritis; Medicines for human purposesfor the treatment of infectious disease; Pharmaceutical preparations for the treatment of autoimmune disorders; Medicines for treating cancer
Publications
History of USPTO decisions and trademark events.
8 publications found
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/28/2021
PUBO
PUBLISHED FOR OPPOSITION
09/28/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/08/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/25/2021
DOCK
ASSIGNED TO EXAMINER
08/25/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/06/2021
NWAP
NEW APPLICATION ENTERED
02/06/2021
Continuous trademark protection
Get notified about every new filing that threatens STAIDSON or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.